Related Experiment Video
Updated: Jul 3, 2026
06:32
Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation
Published on: July 14, 2023
Home-based technologies: a new paradigm for conducting dementia prevention trials
1NIA - Layton Aging & Alzheimer's Disease Center and ORCATECH, the Oregon Center for Aging & Technology, Oregon Health & Science University, Portland, OR, USA. kaye@ohsu.edu
Summary
Future Alzheimer's disease (AD) dementia prevention requires new research paradigms. Ubiquitous home sensing offers frequent, convenient, long-term assessment of aging cohorts to detect subtle changes, improving clinical trial efficiency.
Area of Science:
- Neuroscience
- Gerontology
- Biomedical Engineering
Background:
- Alzheimer's disease (AD) treatment research has established common trial paradigms for efficacy and safety.
- Preventing dementia requires evolving beyond current models to detect meaningful change over extended periods.
Purpose of the Study:
- To outline the need for new paradigms in Alzheimer's disease research.
- To highlight the potential of novel sensing technologies for longitudinal studies.
Main Methods:
- Discusses the limitations of current clinical trial designs for long-term dementia research.
- Proposes the integration of ubiquitous embedded home sensing and computing.
- Emphasizes the need for clinical studies to optimize these new methods.
Main Results:
- Current methods are insufficient for detecting subtle, long-term changes in aging populations.
- Ubiquitous sensing enables frequent, convenient, and prolonged assessment of individuals.
- Capturing variability and heterogeneity in longitudinal aging cohorts is crucial.
Conclusions:
- Future Alzheimer's disease research must incorporate innovative paradigms for dementia prevention.
- Embedded home sensing offers a promising avenue for more efficient and sensitive longitudinal studies.
- Further clinical research is necessary to validate and optimize the use of these advanced assessment tools.
Related Concept Videos
01:29Documentation in Long-Term and Home Healthcare Setting
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...